Trial Profile
Phase I-II Study of HER2 Vaccination With Poly(I) Poly(C12U) (Ampligen) as an Adjuvant in Optimally Treated Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary) ; Cancer vaccine HER-2 neu; Granulocyte macrophage colony stimulating factor; Sargramostim
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 17 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
- 29 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.